Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:32 ET | 524 | 1.68 |
09:36 ET | 400 | 1.695 |
09:38 ET | 554 | 1.71 |
09:39 ET | 7798 | 1.7075 |
09:43 ET | 200 | 1.7003 |
09:48 ET | 2500 | 1.7 |
09:52 ET | 1845 | 1.6908 |
09:59 ET | 300 | 1.6806 |
10:01 ET | 1052 | 1.68 |
10:08 ET | 908 | 1.68 |
10:24 ET | 222 | 1.6813 |
10:30 ET | 1200 | 1.69 |
10:33 ET | 400 | 1.7 |
10:35 ET | 340 | 1.7004 |
10:48 ET | 632 | 1.71 |
11:02 ET | 1371 | 1.71 |
11:20 ET | 200 | 1.7094 |
11:27 ET | 769 | 1.7 |
11:45 ET | 400 | 1.7 |
11:47 ET | 959 | 1.72 |
12:21 ET | 250 | 1.71 |
12:23 ET | 1739 | 1.74 |
12:32 ET | 250 | 1.74 |
12:34 ET | 3102 | 1.75 |
12:38 ET | 500 | 1.7544 |
12:39 ET | 3465 | 1.75 |
12:41 ET | 100 | 1.74 |
12:45 ET | 300 | 1.74 |
12:59 ET | 2000 | 1.7499 |
01:01 ET | 100 | 1.75 |
01:15 ET | 2859 | 1.77 |
01:35 ET | 600 | 1.7503 |
01:42 ET | 300 | 1.75 |
02:04 ET | 100 | 1.74 |
02:36 ET | 221 | 1.72 |
02:38 ET | 900 | 1.72 |
02:44 ET | 2555 | 1.7201 |
03:03 ET | 100 | 1.72 |
03:18 ET | 100 | 1.73 |
03:27 ET | 500 | 1.73 |
03:30 ET | 350 | 1.74 |
03:45 ET | 251 | 1.7406 |
03:48 ET | 425 | 1.7401 |
03:52 ET | 470 | 1.75 |
03:54 ET | 100 | 1.745 |
03:57 ET | 3639 | 1.75 |
03:59 ET | 3751 | 1.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 18.5M | -1.1x | --- |
BullFrog AI Holdings, Inc. | 18.5M | -3.5x | --- |
NanoViricides Inc | 17.7M | -1.8x | --- |
Biomx Inc | 17.6M | -2.3x | --- |
BioVie Inc | 19.3M | -0.1x | --- |
Finch Therapeutics Group Inc | 18.1M | -1.3x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.62 |
Book Value | $-0.14 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.